Articles On Cryosite (ASX:CTE)

Title Source Codes Date
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Stockhead CTE 1 month ago
Closing Bell: Smug ASX ends Tuesday higher, but not much better

The ASX benchmark has ended Tuesday higher 8 of 11 sectors in the green Small caps led by Plenti Group (ASX:PLT), InteliCare (ASX:ICR) The local market has trimmed some of its early gains (wussed out) after jumping out of the blocks in...

Stockhead CTE 4 months ago
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

Stockhead CTE 4 months ago
Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Stockhead CTE 5 months ago
Markets remain cautious ahead of key jobs data

  Stocks settled lower on Thursday as investors remain cautious ahead of key jobs data on Friday that could determine the next move for interest rates. The Dow Jones Industrial Average closed down 10 points, or 0.03 per cent. The S&P 50...

ShareCafe CTE 5 months ago
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

Stockhead CTE 6 months ago
Check Up: What is the FDA emergency use authorisation, and which ASX stocks were given approval?

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Stockhead CTE 6 months ago
Major US indexes fall as Fed rate hike fears return

  Stocks sold off Wednesday, continuing the sluggish start to September, as concerns mounted that the Federal Reserve may not be done hiking interest rates. The Dow Jones Industrial Average sank 198.78 points, or 0.57 per cent, to end at 34...

ShareCafe CTE 6 months ago
Check Up: Australian biotech sector continues to be a magnet for US investors

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Stockhead CTE 6 months ago
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

Stockhead CTE 7 months ago
ASX Biotech Winners in July: Down but far from out, here’s why biotechs could stage a comeback

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Stockhead CTE 7 months ago
Check Up: Brisbane based Vaxxas set to disrupt market with game-changing, needle-free vaccines

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Stockhead CTE 9 months ago
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Stockhead CTE 9 months ago
CLOSING BELL: A massive win for Zelira’s new pain drug has polished an absolute turd of a day

The ASX 200 fell 1.37%, and the bad news kept piling up all day Inflation data knee-capped the market mid-morning, because rate hikes are on the way Two Small Caps hit triple-figure home runs today, which is kinda amazing   Welp… that was...

Stockhead CTE 9 months ago
Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m quarterly sales

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Stockhead CTE 10 months ago
Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Stockhead CTE 1 year ago
Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Stockhead CTE 1 year ago
How out of favour Biotech has a PR problem and could learn from Dr Karl

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Stockhead CTE 1 year ago
BRIEF-Cryosite Ltd Says Unaudited Trading For First Four Months Of Year Show Stable Revenues

Nov 17 (Reuters) - Cryosite Ltd: * UNAUDITED TRADING FOR FIRST FOUR MONTHS OF YEAR SHOW STABLE REVENUES BUT LOWER PROFITABILITY * FOR FIRST 4 MONTHS OF FY23, TOTAL REVENUE FLAT ON PCP AT A$3,791 MILLION Source text for Eikon: Further compan...

Kalkine Media CTE 1 year ago
US equity markets surge off lows despite higher than expected inflation data

ShareCafeUS equity markets surge off lows despite higher than expected inflation data                    US equities finished higher in Thursday trading, near best levels after reversing a big decline from right after the open – this...

ShareCafe CTE 1 year ago
Check Up: Blood clots are a $55bn opportunity and these 2 ASX stocks are vying for a slice

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Stockhead CTE 1 year ago
US markets rise as EV battery integration grows rapidly under Biden Administration

ShareCafeUS markets rise as EV battery integration grows rapidly under Biden Administration                    US equities were mostly higher in fairly choppy Wednesday trading. The Nasdaq Composite ground higher in choppy trading on...

ShareCafe CTE 1 year ago
Check Up: US FDA approves first clinical trial of naturally derived psychedelic drugs

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

Stockhead CTE 1 year ago
Check Up: These biotech themes got billions in VC funding. These ASX stocks could benefit

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Stockhead CTE 1 year ago
Closing Bell: A lithium leak is draining the small cap battery boom

Emerging markets index closes 2.3% lower ASX200 pretty flat, maybe ahead by 0.1% March Qtr GDP rises 0.8%   The Emerging Companies Index has got a lithium leak. We don’t where, we don’t know why. It was down more than 2.7% and has kinda...

Stockhead CTE 1 year ago
Closing Bell: Markets go easy peasy lemon squeezy on Anthony Norman Albanese

Aussie markets opened slightly ahead this morning after man of the moment Anthony Norman Albanese was sworn in as the 31st prime minister and posed for a happy ALP family pic, thus ended 10 years of conservative government. Throughout the d...

Stockhead CTE 1 year ago
Check Up: Money managers are still bullish on Healthcare; here’s what they said

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

Stockhead CTE 1 year ago
Top 10 at 10: These ASX stocks are unstoppable in early trade

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Stockhead CTE 1 year ago
Check Up: Biotechs are going through a rough patch, but recent ASX IPOs haven’t flopped too badly

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Stockhead CTE 1 year ago
Check Up: More clinical trials and FDA funding boost. Is this the end of biotech’s woes?

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Stockhead CTE 1 year ago
Closing Bell: ASX flat, but volatile

ASX Emerging Companies (XEC) index has closed o.2% higher Monday Monday winners: Terramin Australia (ASX:TZN), Frontier Resources (ASX:FNT), Ardea Resources (ASX:ARL) Monday losers: Melbana Energy (ASX:MAY)   The ASX Emerging Companies...

Stockhead CTE 2 years ago
Closing Bell: Small caps rise, unemployment falls, more people accept life’s full of ups and downs

The Emerging Companies Index (XEC) climbed more than 2% higher on Thursday, before closing at 1.9%, while its benchmark colleague – the upmarket ASX 200 followed Wall Street’s ascendence, trading up a shade over 1% after the Fed lifted inte...

Stockhead CTE 2 years ago
Check Up: The future of telehealth, and the best and worst performing ASX health stocks for the month

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

Stockhead CTE 2 years ago
Check Up: Johnson & Johnson manoeuvre causes a stir, as CSL pulls Healthcare higher on the ASX

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

Stockhead CTE 2 years ago
Check Up: As Omicron rages, rapid antigen testing specialist Atomo surges nearly 50pc

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

Stockhead CTE 2 years ago
Check Up: Anteotech riding high with $1.9m refund, and Avecho inks supply agreement for CBD arthritis treatment

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

Stockhead CTE 2 years ago
Healthcare has been a hot sector. Here are the top ASX biotech stocks in 2021

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

Stockhead CTE 2 years ago
Hot Money Monday: Some unusual names post high RSIs while BNPL turns to ice

Each week, Stockhead recaps ASX stocks that are “running hot” as deduced by the Relative Strength Index (RSI). The RSI is a technical gauge which measures how trading momentum is affecting the price action. A reading of 70 is seen as the le...

Stockhead CTE 2 years ago
Closing Bell: ASX edges lower ahead of all-important US inflation data

For the first time in over a month, the ASX finished a week higher than where it began — even with the bourse declining on an intraday basis. The ASX 200 closed at 7,353 points which was 0.42% lower than yesterday, but up 1.6% from last Fri...

Stockhead CTE 2 years ago
Check Up: Neuren close to FDA drug approval and Compumedics fires up Aussie factory for medical wearables

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

Stockhead CTE 2 years ago
Check Up: Sustainable Nutrition riding high and Singular Health branches out from… health

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Stockhead CTE 2 years ago
Check Up: Dimerix and ImpediMed announced breakthroughs, while earnings dominate news flow in August

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

Stockhead CTE 2 years ago
Check up: Rhinomed (ASX:RNO) soars with NSW COVID contract, and genetic testing fails to impress

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

Stockhead CTE 2 years ago
Closing Bell: ASX rises again, hits all time high

The ASX had another positive day but, unlike yesterday, held momentum to close at an all time high. The ASX 200 closed at 7,511 points which was an 0.11% gain although the ASX Emerging Companies Index fell 0.63% to 2,226 points. The top sec...

Stockhead CTE 2 years ago
Check Up: Hexima roars 70pc on clinical trials, while Bionomics heads for a US dual listing

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

Stockhead CTE 2 years ago
Check Up: Rhythm (ASX:RHY) plans US expansion, the US$1.5b dog dermatitis market and data dumps drive stocks down

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

Stockhead CTE 2 years ago
Check up: A mixed bag for ASX health stocks as FDA decides fates at the flip of a coin

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Stockhead CTE 2 years ago
Directors’ Trades: Which Malaysian Rich Listers spent over $38 million on their own ASX stock?

The past fortnight has been quieter for ASX directors trades but two trades from Malaysian directors of United Overseas Australia (ASX:UOS) made up $38 million of the total. United Overseas Australia is a Malaysian property group founded in...

Stockhead CTE 2 years ago
Trajan Group’s shares surge 40% since IPO; can it sustain gains?

Summary Trajan Group Holdings made a strong debut on ASX on June 7, 2021. The MedTech company successfully raised AU$90 million via IPO at a market cap of AU$220 million. The company is expected to achieve revenue of AU$75 million in...

Kalkine Media CTE 2 years ago
Check Up: As Alzheimer’s grabs the spotlight, these ASX biotech stocks also impressed

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Stockhead CTE 2 years ago